Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Pemetrexed Dosing in Renally Impaired NSCLC/Mesothelioma
NCT03656549Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC) and mesothelioma, sponsored by Radboud University Medical Center. Primary endpoint: The fraction of patients safely reaching the target dose at 3 months. Started Feb 2019; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NCT03656549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656549.